Carmat Announces Judicial Liquidation; Genfit Reports Positive Phase 1 Results for G1090N
Carmat has entered judicial liquidation and withdrawn from the stock exchange after being placed under judicial recovery, with a transfer plan approved for Carmat SAS to continue operations. Meanwhile, Genfit reported positive Phase 1 results for its experimental drug G1090N, showing a favorable safety profile and anti-inflammatory activity. Additionally, GTT received an order from Hanwha Ocean for cryogenic tanks for LNG carriers, while Hoffmann Green Cement Technologies prepares to announce its Q4 revenue.
Theia Market Signal Identification - AI Assisted
Carmat has entered judicial liquidation and withdrawn from stock exchange listing after being placed under judicial recovery on July 1. On December 1, the Versailles Economic Activities Tribunal approved a transfer plan to Carmat SAS, which will now operate the company's activities.
Genfit announced that its experimental drug G1090N for ACLF treatment showed a favorable safety profile in a Phase 1 study, demonstrating anti-inflammatory activity in ex vivo tests. GTT has received an order from Hanwha Ocean for the design of cryogenic tanks for seven new LNG carriers for a European shipowner, with delivery expected between 2028 and 2029.
Hoffmann Green Cement Technologies will announce its Q4 revenue. LDC Group remains optimistic, targeting over €7 billion in revenue, reporting €1857 million for Q3 2025-2026, a 17.3% increase year-over-year. SMAIO secured €2 million in non-dilutive funding, including a €1 million zero-interest loan from Bpifrance and the EU.
Comments